Bispecific Antibodies: Navigating From Design To Market Success

Bispecific antibodies (BsAbs) offer immense therapeutic potential, but their development is complex due to the challenges at each development stage. A comprehensive assessment of BsAb formats is needed in order to optimize yield, stability, and functionality. This article proposes a multi-stage evaluation process, beginning with format screening to identify promising candidates based on yield, integrity, and biological activity. The subsequent stages focus on refining expression, as well as upstream and downstream processes. By prioritizing comprehensive evaluation early in development, we can significantly reduce risks, costs, and time-to-market while increasing the likelihood of clinical success. Download the full article to learn more.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.